Australian biopharmaceutical, development company in immunotherapeutics for autoimmune diseases, AIDS, cancers, infectious diseases based on patented Co-X-Gene platform technology co-expressing antibodies and T cells.

Eiffel Technologies undertakes biomedical drug re-engineering using supercritical fluid (SCF) technology platforms to create to sub-micron particles with innovative particle architecture providing improved solubility and bioavailability, for enhanced drug design and delivery.